Drug Development

Bioreactor company receives National Science Foundation grant

Published in Blood Weekly, November 18th, 2004

KBI BioPharma announced that it would receive a $500,000 Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation to support the application of the company's centrifugal bioreactor (CBR) technology to biopharmaceutical production.

The Phase II grant follows successful completion of work under an earlier Phase I grant, and will support design, fabrication, testing and characterization of a pilot-scale bioreactor and its integration into the biopharmaceutical production process.

KBI BioPharma's CBR technology applies advanced fluidized bed methodology to allow cells producing recombinant therapeutic and vaccine...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-11-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry